Valuation: OnKure Therapeutics, Inc.

Market Cap 117M 103M 97.33M 88.7M 166M 11.26B 167M 1.16B 451M 5.75B 441M 431M 18.48B P/E 2026 *
-1.58x
P/E 2027 * -1.9x
Enterprise Value 117M 103M 97.33M 88.7M 166M 11.26B 167M 1.16B 451M 5.75B 441M 431M 18.48B EV / Sales 2026 *
470x
EV / Sales 2027 * 176x
Free-Float
89.55%
Yield 2026 *
-
Yield 2027 * -
1 day-1.02%
1 week-1.69%
Current month-20.11%
1 month-24.68%
3 months-31.28%
6 months-27.50%
1 week 2.86
Extreme 2.86
3.24
1 month 2.82
Extreme 2.815
4.02
Current year 2.23
Extreme 2.23
5.38
1 year 2.23
Extreme 2.23
5.38
3 years 1.7
Extreme 1.7
20
5 years 1.7
Extreme 1.7
20
10 years 1.7
Extreme 1.7
20
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Sell

Chief Financial Officer

-302 0.0007%
21/09/26 Sell

Chief Executive Officer

-87 0.0002%
07/08/26 Free

Director

22,350 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-1.69%+14.17% - 119M
-0.14%+4.33%+9.88%+31.73% 48.01B
-1.69%+1.48%+53.02%+33.59% 45.27B
+2.56%+7.34%+382.17%+594.81% 42.84B
+0.24%+2.85%+9.78%+89.54% 40.93B
-0.62%-1.11%+4.70%+46.02% 29.6B
-0.28%+1.07%+26.83%+152.91% 17.32B
-0.46%+1.20%+26.78%+41.32% 15.34B
-2.21%-4.70% - - 15.15B
+3.37%+9.21%+9.93% - 14.84B
Average -0.02%+1.34%+59.70%+141.42% 26.94B
Weighted average by Cap. +0.08%+1.77%+81.84%+153.92%

Financials

2026 *2027 *
Net sales 250K 219K 207K 189K 353K 23.96M 356K 2.48M 960K 12.24M 939K 918K 39.34M 667K 585K 553K 504K 943K 63.9M 949K 6.61M 2.56M 32.64M 2.5M 2.45M 105M
Net income -64.23M -56.37M -53.23M -48.51M -90.82M -6.16B -91.46M -637M -247M -3.15B -241M -236M -10.11B -70.41M -61.78M -58.35M -53.18M -99.54M -6.75B -100M -698M -270M -3.45B -264M -259M -11.08B
Net Debt - -
Logo OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Employees
45
Date Price Change Volume
25/09/26 $2.900 -1.02% 91,423
24/09/26 $2.930 -0.34% 149,717
23/09/26 $2.940 -5.16% 149,747
22/09/26 $3.100 +1.31% 200,807
21/09/26 $3.060 +3.73% 166,721
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.900USD
Average target price
15.50USD
Spread / Average Target
+434.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OKUR Stock